00:14 , Jul 16, 2019 |  BC Extra  |  Clinical News

July 15 Clinical Quick Takes: Zejula meets in Phase III for 1L ovarian cancer; plus Capricor, Avrobio and NIH

Zejula improves 1L ovarian cancer PFS  Zejula niraparib met the primary endpoint in the Phase III PRIMA trial to treat first-line ovarian cancer following platinum chemotherapy, significantly improving progression-free survival regardless of patients' biomarker status...
10:00 , Apr 18, 2019 |  BC Extra  |  Company News

Talaris raises $100M series A, reports 70% immune tolerance for allogeneic cell therapy

With a new management team at the helm, Talaris raised $100 million in a series A round Thursday and reported that FCR001 led to a 70% immune tolerance rate in a Phase II trial to...
22:29 , Mar 12, 2019 |  BC Extra  |  Company News

Management tracks: Inovio, Sangamo, Innate

Inovio CMO Mark Bagarazzi has left the company. Inovio Pharmaceuticals Inc. (NASDAQ:INO) said a newly formed medical council -- VPs of Clinical Development Prakash Bhuyan, Jeffrey Skolnik and Scott White -- will now oversee the...
20:56 , Mar 8, 2019 |  BioCentury  |  Emerging Company Profile

Synbal: Gene driving on parallel tracks

Synbal is tapping new genetic approaches to develop both rodents with humanized metabolisms and cell therapies for lysosomal storage diseases. Ethan Bier, Valentino Gantz and Tsvi Goldenberg spun out Synbal Inc. from the University of...
19:42 , Oct 5, 2018 |  BC Week In Review  |  Clinical News

Vector copy number declines over time in four Fabry disease patients who received Avrobio gene therapy

Avrobio Inc. (NASDAQ:AVRO) said peripheral blood average vector copy number (VCN) declined over time in four Fabry disease patients who received a single dose of gene therapy AVR-RD-01 in either a Phase I or Phase...
22:07 , Oct 1, 2018 |  BC Extra  |  Clinical News

Avrobio falls on data for Fabry gene therapy

Avrobio Inc. (NASDAQ:AVRO) said peripheral blood average vector copy number (VCN) declined over time in four Fabry disease patients who received a single dose of gene therapy AVR-RD-01 in either a Phase I or Phase...
23:21 , Jul 13, 2018 |  BioCentury  |  Finance

Pause for politics

The near record-setting pace of 1H18 capital markets activity isn’t likely to be replicated this half, but that won’t be because of changes to sector fundamentals. Instead, it’s likely the consequence of macroeconomic and geopolitical...
19:15 , Jun 22, 2018 |  BC Week In Review  |  Financial News

IPO roundup: Avrobio, Aptinyx, Magenta, Kezar, Xeris

Five biopharmas priced IPOs late on June 20, raising a total of more than $460 million. Four of the five upsized their offerings to sell more shares than anticipated; one of those, Avrobio, also priced...
04:46 , Jun 21, 2018 |  BC Extra  |  Financial News

Four companies in IPO quintet post first-day gains

Four of the five biopharmas that priced IPOs late Wednesday posted gains on Thursday. Cell therapy company Avrobio Inc. (NASDAQ:AVRO) had the biggest first-day bump, climbing $12.20 (64%) to $31.20, while three others posted double-digit...
19:14 , Jun 1, 2018 |  BC Week In Review  |  Financial News

Avrobio proposes $86.3M NASDAQ IPO

Avrobio Inc. (Cambridge, Mass.) proposed on May 25 to raise $86.3 million in an IPO underwritten by Morgan Stanley, Cowen, Wells Fargo and Wedbush PacGrow. In February, the cell therapy company raised $60 million in...